Literature DB >> 6751835

Nonlinear plasma protein binding and haemodialysis clearance of prednisolone.

F J Frey, J G Gambertoglio, B M Frey, L Z Benet, W J Amend.   

Abstract

The impact of nonlinear plasma protein binding of a drug on its removal by haemodialysis has been quantified. Prednisolone 10-100 mg was given i.v. to 10 renal transplant patients on haemodialysis for acute tubular necrosis. Dialysate and afferent and efferent blood samples were collected simultaneously in 67 instances. Total and unbound prednisolone in plasma and its total concentration in blood and dialysate were assessed by high performance liquid chromatography and equilibrium dialysis. The amount of prednisolone lost, as measured directly in the dialysate (21.8 +/- 4.4 micrograms/min, mean +/- SE), was predictable from the afferent-efferent blood concentration differences (20.1 +/- 4.8 micrograms/min), but not from measurements of total afferent-efferent prednisolone concentrations in plasma (13.1 +/- 3.0 micrograms/min). The amount of prednisolone lost in the dialysate increased linearly with unbound (r2 = 0.96) and hyperbolically with the total prednisolone concentration in plasma. The latter hyperbolic relationship is adequately described by the equation for nonlinear plasma protein binding, using the affinity and capacity constants of albumin and transcortin for prednisolone (r2 = 0.98). Thus, the haemodialysis clearance of total prednisolone is concentration-dependent, while the clearance of unbound prednisolone is constant (76 ml/min). Free clearance values or measurements of afferent-efferent blood concentrations are mandatory for a drug showing nonlinear plasma protein binding in order to predict the amount lost in the dialysate.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6751835     DOI: 10.1007/bf01061379

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Role of concentration-dependent plasma protein binding in disopyramide disposition.

Authors:  P J Meffin; E W Robert; R A Winkle; S Harapat; F A Peters; D C Harrison
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

2.  Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation.

Authors:  N Gerber; J G Wagner
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1972-05

3.  Binding of anilide-type local anesthetics in human plasma. I. Relationships between binding, physicochemical properties, and anesthetic activity.

Authors:  G T Tucker; R N Boyes; P O Bridenbaugh; D C Moore
Journal:  Anesthesiology       Date:  1970-09       Impact factor: 7.892

4.  Pharmacokinetics of prednisolone and endogenous hydrocortisone levels in cushingoid and non-cushingoid patients.

Authors:  F J Frey; W J Amend; F Lozada; B M Frey; N H Holford; L Z Benet
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

5.  Liquid-chromatographic measurement of endogenous and exogenous glucocorticoids in plasma.

Authors:  F J Frey; B M Frey; L Z Benet
Journal:  Clin Chem       Date:  1979-11       Impact factor: 8.327

6.  Pharmacokinetics of salicylate elimination in man.

Authors:  G Levy
Journal:  J Pharm Sci       Date:  1965-07       Impact factor: 3.534

7.  Observations on the antirheumatic and physiologic effects of phenylbutazone (butazolidin) and some comparisons with cortisone.

Authors:  B B BRODIE; E W LOWMAN; J J BURNS; P R LEE; T CHENKIN; A GOLDMAN; M WEINER; J M STEELE
Journal:  Am J Med       Date:  1954-02       Impact factor: 4.965

8.  Clearance calculations in hemodialysis: application to blood, plasma, and dialysate measurements for ethambutol.

Authors:  C S Lee; T C Marbury; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1980-02

9.  A single dose of azathioprine does not affect the pharmacokinetics of prednisolone following oral prednisone.

Authors:  F J Frey; F Lozada; T Guentert; B M Frey
Journal:  Eur J Clin Pharmacol       Date:  1981-02       Impact factor: 2.953

Review 10.  Drug therapy in renal failure: dosing guidelines for adults. Part I: Antimicrobial agents, analgesics.

Authors:  W M Bennett; R S Muther; R A Parker; P Feig; G Morrison; T A Golper; I Singer
Journal:  Ann Intern Med       Date:  1980-07       Impact factor: 25.391

View more
  8 in total

Review 1.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  B M Frey; F J Frey
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

2.  High haemodialysis clearance of ornidazole in the presence of a negligible renal clearance.

Authors:  F F Horber; O Maurer; P J Probst; E Heizmann; F J Frey
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease.

Authors:  F Keller; M Maiga; H H Neumayer; H Lode; A Distler
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jul-Sep       Impact factor: 2.441

Review 4.  Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation.

Authors:  Troels K Bergmann; Katherine A Barraclough; Katie J Lee; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

Review 5.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

6.  Prednisolone protein binding in renal transplant patients.

Authors:  P A Reece; A P Disney; I Stafford; J C Shastry
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

7.  Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis.

Authors:  D E Uehlinger; F Schaedeli; M Kinzig; F Sörgel; F J Frey
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 8.  Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

Authors:  C S Lee; T C Marbury
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.